Regional treatment strategies for in-transit melanoma metastasis

Surgical Oncology Clinics of North America

Volumn 20, Issue 1, 2011, Pages 79-103

  Turley, Ryan S ^a   Raymond, Amanda K ^a   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

In transit; Isolated limb infusion; Isolated limb perfusion; Melanoma; Regional chemotherapy

Indexed keywords

6 O BENZYLGUANINE; ALPHA2A INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DACARBAZINE; DASATINIB; EVEROLIMUS; EXHERIN; GAMMA INTERFERON; MELPHALAN; PACLITAXEL; SORAFENIB; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; DNA REPAIR; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION PROFILING; HUMAN; HYPOTHERMIC ISOLATED LIMB PERFUSION; IMMUNOMODULATION; IN-TRANSIT METASTASIS; INFLAMMATION; INTERMETHOD COMPARISON; ISOLATED LIMB INFUSION; LIMB DISEASE; LOW DRUG DOSE; MELANOMA; NONHUMAN; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; THERAPY; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; DISEASE PROGRESSION; HUMANS; MELANOMA; MELPHALAN; NEOPLASM METASTASIS; NEOPLASM STAGING; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 78649478314     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.09.008     Document Type: Review

References (145)

1. Weinstock M.A. Do sunscreens increase or decrease melanoma risk: an epidemiologic evaluation. J Investig Dermatol Symp Proc 1999, 4(1):97-100.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
3. de Vries E., Bray F.I., Coebergh J.W., et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003, 107(1):119-126.
4. Pawlik T.M., Ross M.I., Johnson M.M., et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005, 12(8):587-596.
5. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-6206.
6. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19(16):3635-3648.
7. Meier F., Will S., Ellwanger U., et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002, 147(1):62-70.
8. Cascinelli N., Bufalino R., Marolda R., et al. Regional nonnodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986, 12(2):175-180.
9. Calabro A., Singletary S.E., Balch C.M. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989, 124(9):1051-1055.
10. Zogakis T.G., Bartlett D.L., Libutti S.K., et al. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001, 8(10):771-778.
11. Dong X.D., Tyler D., Johnson J.L., et al. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 2000, 88(5):1063-1071.
12. Bhatia S., Tykodi S.S., Thompson J.A. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009, 23(6):488-496.
13. Minor D.R., Allen R.E., Alberts D., et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985, 55(11):2638-2644.
14. Storm F.K., Morton D.L. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985, 150(1):32-35.
15. Kroon B.B., Van Geel A.N., Benckhuijsen C., et al. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res 1987, 7(3 Pt B):441-442.
16. Kroon B.B., Klaase J.M., van Geel B.N., et al. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer 1993, 29A(3):325-328.
17. Klaase J.M., Kroon B.B., van Geel A.N., et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994, 115(1):39-45.
18. Grünhagen D.J., Brunstein F., Graveland W.J., et al. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004, 240(6):939-947. [discussion: 947-8].
19. Aloia T.A., Grubbs E., Onaitis M., et al. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg 2005, 140(11):1115-1120.
20. Cornett W.R., McCall L.M., Petersen R.P., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006, 24(25):4196-4201.
21. Sanki A., Kam P.C., Thompson J.F. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007, 245(4):591-596.
22. Mian R., Henderson M.A., Speakman D., et al. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 2001, 44(3):189-192.
23. Lindner P., Doubrovsky A., Kam P.C., et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002, 9(2):127-136.
24. Bonenkamp J.J., Thompson J.F., de Wilt J.H., et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004, 30(10):1107-1112.
25. Brady M.S., Brown K., Patel A., et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006, 13(8):1123-1129.
26. Kroon H.M., Moncrieff M., Kam P.C., et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008, 15(11):3003-3013.
27. Beasley G.M., Caudle A., Petersen R.P., et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009, 208(5):706-715. [discussion: 715-7].
28. Creech O., Ryan R.F., Krementz E.T. Regional chemotherapy by isolated perfusion in the treatment of melanoma of the extremities. Plast Reconstr Surg Transplant Bull 1961, 28:333-346.
29. Creech O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958, 148(4):616-632.
30. Beasley G.M., Petersen R.P., Yoo J., et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008, 15(8):2195-2205.
31. Thompson J.F., Kam P.C., Waugh R.C., et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998, 14(3):238-247.
32. Thompson J.F., Waugh R.C., Saw R.P.M., et al. Isolated limb infusion with melphalan: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994, 7:188-192.
33. Santillan A.A., Delman K.A., Beasley G.M., et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009, 16(9):2570-2578.
34. Padussis J.C., Steerman S.N., Tyler D.S., et al. Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI. Int J Hyperthermia 2008, 24(3):239-249.
35. Kroon H.M., Moncrieff M., Kam P.C., et al. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 2009, 16(5):1184-1192.
36. Benckhuijsen C., Kroon B.B., van Geel A.N., et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988, 14(2):157-163.
37. Cavaliere R., Ciocatto E.C., Giovanella B.C., et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967, 20(9):1351-1381.
38. Thompson J.F., Lai D.T., Ingvar C., et al. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994, 4S:45-50.
39. Wu Z.Y., Smithers B.M., Roberts M.S. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J Pharmacol Exp Ther 1997, 282(3):1131-1138.
40. Eggermont A.M., de Wilt J.H., ten Hagen T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003, 4(7):429-437.
41. Luce J.K. Chemotherapy of malignant melanoma. Cancer 1972, 30(6):1604-1615.
42. Roberts M.S., Wu Z.Y., Siebert G.A., et al. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res 2001, 11(6):611-618.
43. Taber S.W., Polk H.C. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol 1997, 4(5):440-445.
44. Cheng T.Y., Grubbs E., Abdul-Wahab O., et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg 2003, 186(5):460-467.
45. Vrouenraets B.C., Hart G.A., Eggermont A.M., et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999, 188(5):522-530.
46. Beasley G.M., McMahon N., Sanders G., et al. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 2009, 115:4766-4774.
47. Di Filippo F., Calabro A., Giannarelli D., et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989, 63(12):2551-2561.
48. Engler H.S., Sweat R.D. Volumetric arm measurements: technique and results. Am Surg 1962, 28:465-468.
49. McMahon N., Cheng T.Y., Beasley G.M., et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?. Ann Surg Oncol 2009, 16(4):953-961.
50. Thompson J.F., Gianoutsos M.P. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992, 16(2):227-233.
51. Wile A.G., Guilmette E., Friedberg H., et al. A model of experimental isolation perfusion using cis-platinum. J Surg Oncol 1982, 21(1):37-41.
52. Aigner K., Hild P., Henneking K., et al. Regional perfusion with cis-platinum and dacarbazine. Recent Results Cancer Res 1983, 86:239-245.
53. Roseman J.M. Effective management of extremity cancers using cisplatin and etoposide in isolated limb perfusions. J Surg Oncol 1987, 35(3):170-172.
54. Klein E.S., Ben-Ari G.Y. Isolation perfusion with cisplatin for malignant melanoma of the limbs. Cancer 1987, 59(6):1068-1071.
55. Pommier R.F., Moseley H.S., Cohen J., et al. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg 1988, 155(5):667-671.
56. Hajarizadeh H., Mueller C.R., Woltering E.A., et al. Phase I-II trial of hyperthermic isolated limb perfusion with cisplatin in the treatment of high risk malignant melanoma of the extremities. Melanoma Res 1991, 1(1):55-61.
57. Santinami M., Belli F., Cascinelli N., et al. Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities. J Surg Oncol 1989, 42(3):201-208.
58. Coit D.G., Bajorin D.F., Menendez-Botet C. A phase I trial of hyperthermic isolation limb perfusion (HILP) using cisplatin (CDDP) for metastatic melanoma. Proceedings of ASCO 1991, 10:294.
59. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18(1):158-166.
60. Agarwala S.S., Kirkwood J.M. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000, 5(2):144-151.
61. Ueno T., Ko S.H., Grubbs E., et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther 2006, 5(3):732-738.
62. Yoshimoto Y., Augustine C.K., Yoo J.S., et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther 2007, 6(5):1492-1500.
63. Yao K.A., Hsueh E.C., Essner R., et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?. Ann Surg 2003, 238(5):743-747.
64. Alexander H.R., Fraker D.L., Bartlett D.L., et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 2010, 28(1):114-118.
65. Dahl O., Mella O. Hyperthermia and chemotherapeutic agents 1990, Taylor and Francis, New York.
66. Hahn G.M. Potential for therapy of drugs and hyperthermia. Cancer Res 1979, 39(6 Pt 2):2264-2268.
67. Wallah D.F.H. Basic mechanisms of tumor thermotherapy. J Mol Med 1977, 17:381-403.
68. Huang S.K., Stauffer P.R., Hong K., et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 1994, 54(8):2186-2191.
69. Stehlin J.S. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969, 129(2):305-308.
70. Ghussen F., Kruger I., Smalley R.V., et al. Hyperthermic perfusion with chemotherapy for melanoma of the extremities. World J Surg 1989, 13(5):598-602.
71. Ko S.H., Ueno T., Yoshimoto Y., et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 2006, 12(1):289-297.
72. Abdel-Wahab O.I., Grubbs E., Viglianti B.L., et al. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res 2004, 10(17):5919-5929.
73. Posner M.C., Lienard D., Lejeune F.J., et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am 1995, 1(4):274-280.
74. Brouckaert P.G., Leroux-Roels G.G., Guisez Y., et al. In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 1986, 38(5):763-769.
75. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10(1):52-60.
76. Lejeune F.J., Eggermont A.M. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 2007, 25(11):1449-1450. author reply 1450-1441.
77. Garrido-Laguna I., Ponz M., Espinos J. Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?. J Clin Oncol 2007, 25(9):1149. author reply 1149-1151.
78. Depeille P., Cuq P., Passagne I., et al. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer 2005, 93(2):216-223.
79. Harkey M.A., Czerwinski M., Slattery J., et al. Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest 2005, 23(1):19-25.
80. Grubbs E.G., Abdel-Wahab O., Cheng T.Y., et al. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J Am Coll Surg 2004, 199(3):419-427.
81. Buller A.L., Clapper M.L., Tew K.D. Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines. Mol Pharmacol 1987, 31(6):575-578.
82. Suzukake K., Petro B.J., Vistica D.T. Reduction in glutathione content of L-PAM resistant L1210 Cells confers drug sensitivity. Biochem Pharmacol 1982, 31(1):121-124.
83. Townsend D.M., Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22(47):7369-7375.
84. Okamura T., Singh S., Buolamwini J., et al. Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. J Biol Chem 2009, 284(25):16979-16989.
85. McClean S., Hill B.T. An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro. Biochim Biophys Acta 1992, 1114(2-3):107-127.
86. Suzukake K., Vistica B.P., Vistica D.T. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 1983, 32(1):165-167.
87. Strumeyer D.H., Bloch K. Some properties of gamma-glutamylcysteine synthetase. J Biol Chem 1960, 235:PC27.
88. Griffith O.W., Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979, 254(16):7558-7560.
89. Biroccio A., Benassi B., Fiorentino F., et al. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004, 6(3):195-206.
90. McIlwain C.C., Townsend D.M., Tew K.D. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006, 25(11):1639-1648.
91. Pellizzari Tregno F., Sau A., Pezzola S., et al. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma. Eur J Cancer 2009, 45(14):2606-2617.
92. Toshimitsu H., Yoshimoto Y., Augustine C.K., et al. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol 2010, 17:2247-2254.
93. Bignami M., O'Driscoll M., Aquilina G., et al. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res 2000, 462(2-3):71-82.
94. Augustine C.K., Yoo J.S., Potti A., et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 2009, 15(2):502-510.
95. Pegg A.E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990, 50(19):6119-6129.
96. Cheng C.L., Johnson S.P., Keir S.T., et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005, 4(9):1364-1368.
97. Boulton S., Pemberton L.C., Porteous J.K., et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 1995, 72(4):849-856.
98. Haince J.F., Rouleau M., Hendzel M.J., et al. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol Med 2005, 11(10):456-463.
99. Tentori L., Leonetti C., Scarsella M., et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003, 9(14):5370-5379.
100. Augustine C.K., Yoshimoto Y., Gupta M., et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008, 68(10):3777-3784.
101. Hsu M.Y., Wheelock M.J., Johnson K.R., et al. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1996, 1(2):188-194.
102. Hsu M.Y., Meier F.E., Nesbit M., et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000, 156(5):1515-1525.
103. Beasley G, Riboh JC, Augustine CK, et al. A prospective multi-center phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion (M-ILI) in patients with advanced extremity melanoma. In Submission.
104. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
105. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342.
106. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676.
107. Pallis A.G., Serfass L., Dziadziusko R., et al. Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 2009, 45(14):2473-2487.
108. Woolam G.L. Cancer statistics, 2000: a benchmark for the new century. CA Cancer J Clin 2000, 50(1):6.
109. Hainsworth J.D., Infante J.R., Spigel D.R., et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010, 116:4122-4129.
110. Vihinen P.P., Hernberg M., Vuoristo M.S., et al. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res 2010, 20:318-325.
111. Perez D.G., Suman V.J., Fitch T.R., et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a north central cancer treatment group study, N047A. Cancer 2009, 115(1):119-127.
112. Smalley K.S., Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 2005, 1059:16-25.
113. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445(7130):851-857.
114. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
115. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008, 134(2):379.
116. Stein M.N., Flaherty K.T. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007, 13(13):3765-3770.
117. Wilhelm S.M., Adnane L., Newell P., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7(10):3129-3140.
118. Panka D.J., Wang W., Atkins M.B., et al. The Raf inhibitor BAY 43-9006 (sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006, 66(3):1611-1619.
119. Rahmani M., Davis E.M., Bauer C., et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005, 280(42):35217-35227.
120. Yu C., Bruzek L.M., Meng X.W., et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005, 24(46):6861-6869.
121. Gray-Schopfer V.C., Karasarides M., Hayward R., et al. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res 2007, 67(1):122-129.
122. Sharma A., Trivedi N.R., Zimmerman M.A., et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005, 65(6):2412-2421.
123. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95:581-586.
124. Escudier B., Lassau N., Angevin E., et al. Phase I trial of sorafenib in combination with IFN {alpha}-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007, 13(6):1801-1809.
125. Bharti A.C., Donato N., Singh S., et al. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003, 101(3):1053-1062.
126. McDermott D.F., Sosman J.A., Gonzalez R., et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients With advanced melanoma: a report from the 11715 study group. J Clin Oncol 2008, 26(13):2178-2185.
127. Amaravadi R.K., Schuchter L.M., McDermott D.F., et al. Phase II Trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009, 15:7711-7718.
128. Hauschild A., Agarwala S.S., Trefzer U., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27(17):2823-2830.
129. Augustine C.K., Toshimitsu H., Jung S.H., et al. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther 2010, 9:2090-2101.
130. Yeatman T.J. A renaissance for SRC. Nat Rev Cancer 2004, 4(6):470-480.
131. Niu G., Bowman T., Huang M., et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002, 21(46):7001-7010.
132. Niu G., Wright K.L., Huang M., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21(13):2000-2008.
133. Brave M., Goodman V., Kaminskas E., et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008, 14(2):352-359.
134. Homsi J., Cubitt C.L., Zhang S., et al. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res 2009, 19(3):167-175.
135. Yuan J., Gnjatic S., Li H., et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008, 105(51):20410-20415.
136. Alexandrescu D.T., Ichim T.E., Riordan N.H., et al. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010, 33(6):570-590.
137. Barbour A.P., Thomas J., Suffolk J., et al. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol 2009, 16(12):3463-3472.
138. Bild A., Febbo P.G. Application of a priori established gene sets to discover biologically important differential expression in microarray data. Proc Natl Acad Sci U S A 2005, 102(43):15278-15279.
139. John T., Black M.A., Toro T.T., et al. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 2008, 14(16):5173-5180.
140. Winnepenninckx V., Lazar V., Michiels S., et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006, 98(7):472-482.
141. Augustine C.K., Jung S.H., Sohn I., et al. Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther 2010, 9(4):779-790.
142. Middleton M.R., Lunn J.M., Morris C., et al. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998, 78(9):1199-1202.
143. Middleton M.R., Lee S.M., Arance A., et al. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000, 88(3):469-473.
144. Ma S., Egyhazi S., Martenhed G., et al. Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. Melanoma Res 2002, 12(4):335-342.
145. Rietschel P., Wolchok J.D., Krown S., et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008, 26(14):2299-2304.